Palmar plantar erythrodysesthesia causes
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia causes On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia causes |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
|
Risk calculators and risk factors for Palmar plantar erythrodysesthesia causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Several different Chemotherapeutic agents have been associated with acral erythema[1]
Causes
Chemotherapy drugs that can cause this syndrome include:
Most frequently associated:
- Cytarabine (Cytosar-U) [2] [3]
- Docetaxel(Docefrez, Taxotere) [4] [5]
- Doxorubicin (Adriamycin) [6] [7] and liposomal-encapsulated doxorubicin(Doxil) [8] [9] [10] [11] [12] [13] [14]
- 5-Fluorouracil26-41 (5-FU, Adrucil)
- Capecitabine8,42-47 (Xeloda)
- Sorafenib [15]
Less frequently associated:
- Cisplatin48
- Cyclophosphamide49
- Daunorubicin and liposomal daunorubicin50
- Doxifluridine
- Etoposide51-54
- Floxuridine55 (FUDF)
- Hydroxyurea56,57 (hydroxycarbamide)
- 6-Mercaptopurine9
- Methotrexate58-63
- Mitotane1
- Paclitaxel64-67 (Taxol)
- Tegafur68-70
- Vinorelbine71-74
- Idarubicin (Idamycin)
- Vemurafenib75 (Zelboraf)
- 6-thioguanine76
Commonly associated chemotherapeutic agents are listed below:
- Most frequently associated with Doxorubicin (Pegylated liposomal Doxorubicin), 5-Flurouracil, and Cytarabine[16].
- Methotrexate - even low dose used to treat ALL[17]
- Mitotane[18]
- PLD, Docetaxel, Capecitabine, vinorelbine, gemcitabine and Sorafenib[15]
Less Common Causes[19]
- Cisplatin
- Cyclophosphamide
- Daunorubicin
- Doxifluridine
- Etoposide
- Floxuridine
- Hydroxyurea
- Idarubicin
- Lomustine
- Melphalan
- Mercaptopurine
- Mitomycin
- Paclitaxel
- Suramin
- Troxacitabine[20]
- Tegafur
- Vincristine
Genetics
No genetic association has been found as of yet as the data on this condition is limited.
References
- ↑ Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
- ↑ Baer MR, King LE, Wolff SN (1985). "Palmar-plantar erythrodysesthesia and cytarabine". Ann Intern Med. 102 (4): 556. doi:10.7326/0003-4819-102-4-556_1. PMID 3977204.
- ↑ Crawford JH, Eikelboom JW, McQuillan A (2002). "Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia". Eur J Haematol. 69 (5–6): 315–7. PMID 12460237.
- ↑ Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J; et al. (1995). "Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent". Arch Dermatol. 131 (2): 202–6. PMID 7857119.
- ↑ Katoh M, Kadota M, Nishimura Y (2004). "A case of docetaxel-induced erythrodysesthesia". J Dermatol. 31 (5): 403–6. PMID 15187308.
- ↑ Amantea M, Newman MS, Sullivan TM, Forrest A, Working PK (1999). "Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs". Hum Exp Toxicol. 18 (1): 17–26. doi:10.1177/096032719901800103. PMID 10025364.
- ↑ Charrois GJ, Allen TM (2003). "Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity". J Pharmacol Exp Ther. 306 (3): 1058–67. doi:10.1124/jpet.103.053413. PMID 12808004.
- ↑ D'Agostino G, Ferrandina G, Ludovisi M, Testa A, Lorusso D, Gbaguidi N; et al. (2003). "Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer". Br J Cancer. 89 (7): 1180–4. doi:10.1038/sj.bjc.6601284. PMC 2394291. PMID 14520442.
- ↑ Vogelzang NJ, Ratain MJ (1985). "Cancer chemotherapy and skin changes". Ann Intern Med. 103 (2): 303–4. doi:10.7326/0003-4819-103-2-303_3. PMID 3160276.
- ↑ Coukell AJ, Spencer CM (1997). "Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma". Drugs. 53 (3): 520–38. doi:10.2165/00003495-199753030-00011. PMID 9074848.
- ↑ Goram AL, Richmond PL (2001). "Pegylated liposomal doxorubicin: tolerability and toxicity". Pharmacotherapy. 21 (6): 751–63. PMID 11401188.
- ↑ Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y; et al. (2004). "Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer". Ann Oncol. 15 (3): 517–25. doi:10.1093/annonc/mdh092. PMID 14998859.
- ↑ Molpus KL, Anderson LB, Craig CL, Puleo JG (2004). "The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma". Gynecol Oncol. 93 (2): 513–6. doi:10.1016/j.ygyno.2004.02.019. PMID 15099971.
- ↑ Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE (1998). "Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model". Clin Cancer Res. 4 (6): 1567–71. PMID 9626479.
- ↑ 15.0 15.1 Farr KP, Safwat A (2011). "Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment". Case Rep Oncol. 4 (1): 229–35. doi:10.1159/000327767. PMC 3085037. PMID 21537373.
- ↑ Webster-Gandy JD, How C, Harrold K (2007). "Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre". Eur J Oncol Nurs. 11 (3): 238–46. doi:10.1016/j.ejon.2006.10.004. PMID 17350337.
- ↑ Wysocki M, Nowaczyk-Michalak A, Pilecki O, Kurylak A, Balcar-Boroń A, Trybuś L (1992). "[Burgdorf's reaction (painful acral erythema) in patients with acute lymphoblastic leukemia following medium-dose methotrexate therapy]". Wiad Lek. 45 (11–12): 462–4. PMID 1441532.
- ↑ Zuehlke RL (1974). "Erythematous eruption of the palms and soles associated with mitotane therapy". Dermatologica. 148 (2): 90–2. PMID 4276191.
- ↑ Susser WS, Whitaker-Worth DL, Grant-Kels JM (1999). "Mucocutaneous reactions to chemotherapy". J Am Acad Dermatol. 40 (3): 367–98, quiz 399-400. PMID 10071309.
- ↑ Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C; et al. (2001). "Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies". J Clin Oncol. 19 (13): 3267–79. doi:10.1200/JCO.2001.19.13.3267. PMID 11432895.